Bayer AG's gross profit for the
three
months ended in Mar. 2026 was CHF7,439 Mil. Bayer AG's gross profit for the trailing twelve months (TTM) ended in Mar. 2026 was CHF24,893 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Bayer AG's gross profit for the
three
months ended in Mar. 2026 was CHF7,439 Mil. Bayer AG's Revenue for the
three
months ended in Mar. 2026 was CHF12,201 Mil. Therefore, Bayer AG's Gross Margin % for the quarter that ended in Mar. 2026 was 60.97%.
Bayer AG had a gross margin of 60.97% for the quarter that ended in Mar. 2026 => Durable competitive advantage
During the past 13 years, the highestGross Margin % of Bayer AG was 67.49%. The lowest was 53.77%. And the median was 59.16%.
Bayer AG (XSWX:BAYN) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Bayer AG had a gross margin of 60.97% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Bayer AG Gross Profit Related Terms
Bayer AG Gross Profit Historical Data
* Premium members only.
The historical data trend for Bayer AG's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BAYN vs LLY, JNJ, ABBV: Gross Profit Comparison
For the Drug Manufacturers - General subindustry, Bayer AG's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bayer AG Gross Profit vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bayer AG's Gross Profit distribution charts can be found below:
* The bar in red indicates where Bayer AG's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF24,893 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Bayer AG (XSWX:BAYN) has a Gross Profit of CHF24,893 Mil as of Mar. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Bayer AG and its competitors.
Is Bayer AG's Gross Profit too high?
Bayer AG's current Gross Profit is CHF24,893 Mil. Overall, Bayer AG has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's Gross Profit compare to LLY and JNJ?
Bayer AG's Gross Profit of CHF24,893 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Drug Manufacturers company?
A good Gross Profit depends on the Drug Manufacturers industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Bayer AG and its competitors. Bayer AG's current Gross Profit is CHF24,893 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (XSWX:BAYN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF25.89, compared to a current price of CHF47.36 — trading 82.9% above its estimated fair value. The current Gross Profit is CHF24,893 Mil. Bayer AG's overall GF Score™ is 35/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Bayer AG (XSWX:BAYN), the current Gross Profit is CHF24,893 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bayer AG (XSWX:BAYN) Overvalued in 2026?
Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued.
The current stock price of CHF47.36 is trading 82.9% above its estimated GF Value™ of CHF25.89.
GuruFocus considers Bayer AG to be Significantly Overvalued.
Key valuation signals for XSWX:BAYN:
Gross Profit: CHF24,893 Mil
GF Value™: CHF25.89 vs. price of CHF47.36 (82.9% above fair value)
No single metric tells the full story. See the XSWX:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
35GF Score
Get the complete analysis for XSWX:BAYN
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BAYN has been successfully added to your 
